Last reviewed · How we verify
Topotecan and Taxotere
At a glance
| Generic name | Topotecan and Taxotere |
|---|---|
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (PHASE3)
- SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (PHASE3)
- Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer (PHASE2)
- Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer (PHASE2)
- Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer (PHASE3)
- Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas (PHASE3)
- Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer (PHASE3)
- Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topotecan and Taxotere CI brief — competitive landscape report
- Topotecan and Taxotere updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI